AZN vs DOUG · P/E 28, $288.38B cap vs rev $1.03B
AstraZeneca PLC (AZN) versus Douglas Elliman Inc (DOUG) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
Douglas Elliman Inc (DOUG) is a real estate services company listed on US.
AZN does not have a complete income-statement cache yet.
Latest reported DOUG revenue for 2025-12-31 was $1.03B. Net income was $15.2M. Revenue was up 3.8% from 2024-12-31 to 2025-12-31. DOUG currently screens at market cap $214.7M.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. DOUG currently screens at market cap $214.7M.
Not investment advice. Open the AZN and DOUG stock pages for the full models.
Not investment advice.